dc.contributor.author | Aldámiz-Echevarria, Teresa | |
dc.contributor.author | Berenguer, Juan | |
dc.contributor.author | Miralles, Pilar | |
dc.contributor.author | Jimenez-Sousa, Maria Angeles | |
dc.contributor.author | Carrero, Ana | |
dc.contributor.author | Pineda-Tenor, Daniel | |
dc.contributor.author | Díez, Cristina | |
dc.contributor.author | Tejerina, Francisco | |
dc.contributor.author | Pérez-Latorre, Leire | |
dc.contributor.author | Bellón, José M | |
dc.contributor.author | Resino, Salvador | |
dc.date.accessioned | 2018-03-06T10:39:44Z | |
dc.date.available | 2018-03-06T10:39:44Z | |
dc.date.issued | 2016-02-05 | |
dc.identifier.citation | PLoS One. 2016; 11(2): e0148537 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/5668 | |
dc.description.abstract | BACKGROUND: Higher serum levels of adhesion molecules (sICAM-1 and sVCAM-1) are associated with advanced liver fibrosis in patients coinfected with human immunodeficiency virus and hepatitis C virus. We assessed the relationship between serum levels of adhesion molecules and liver-related events (LRE) or death, in coinfected patients. METHODS: We studied clinical characteristics and outcomes of 182 coinfected patients with a baseline liver biopsy (58 with advanced fibrosis) and simultaneous plasma samples who were followed for median of 9 years. We used receiver-operating characteristic (ROC) curves to calculate optimized cutoff values (OCV) of sICAM-1 and sVCAM-1, defined as the values with the highest combination of sensitivity and specificity for LRE. We used multivariate regression analysis to test the association between OCVs of sICAM-1 and sVCAM-1 and outcomes. The variables for adjustment were age, HIV transmission category, liver fibrosis, baseline CD4+ T-cell counts, antiretroviral therapy, and sustained virologic response (SVR). RESULTS: During the study period 51 patients had SVR, 19 had LRE, and 16 died. The OCVs for LRE were 5.68 Log pg/mL for sICAM-1 and 6.25 Log pg/mL for sVCAM-1, respectively. The adjusted subhazard ratio (aSHR) (95% confidence interval [CI]) of death or LRE, whichever occurred first, for sICAM-1 and sVCAM-1 > OCV were 3.98 ([1.14; 13.89], P = 0.030) and 2.81 ([1.10; 7.19], respectively (P = 0.030). CONCLUSIONS: Serum levels of sICAM-1 and sVCAM-1 can serve as markers of outcome in HIV/HCV-coinfected patients. Therapies targeting necroinflammatory damage and fibrogenesis may have a role in the management chronic hepatitis C. | es_ES |
dc.description.sponsorship | This work was supported by grants PI11/01556, PI14/01094, PI11/00245 and CIII/00011
given by Fondo de Investigación de Sanidad en España (FIS) (Spanish Health Funds for Research) and by grants RD12/0017/0004 and RD12/0017/0024 from Plan Nacional R+D+I and cofinanced by ISCIII Subdirección General de Evaluación y el Fondo
Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS; Refs INT10/009 and INT12/154). DPTand MAJS are supported by ISCIII grants CM12/
00043 and CD13/00013, respectively. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Public Library of Science (PLOS) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject | Adult | es_ES |
dc.subject | Biomarkers | es_ES |
dc.subject | CD4-Positive T-Lymphocytes | es_ES |
dc.subject | Coinfection | es_ES |
dc.subject | Female | es_ES |
dc.subject | Follow-Up Studies | es_ES |
dc.subject | HIV Infections | es_ES |
dc.subject | Hepatitis C | es_ES |
dc.subject | Humans | es_ES |
dc.subject | Intercellular Adhesion Molecule-1 | es_ES |
dc.subject | Kaplan-Meier Estimate | es_ES |
dc.subject | Liver Cirrhosis | es_ES |
dc.subject | Male | es_ES |
dc.subject | Retrospective Studies | es_ES |
dc.subject | Vascular Cell Adhesion Molecule-1 | es_ES |
dc.title | Soluble Adhesion Molecules in Patients Coinfected with HIV and HCV: A Predictor of Outcome | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 26849641 | es_ES |
dc.format.volume | 11 | es_ES |
dc.format.number | 2 | es_ES |
dc.format.page | e0148537 | es_ES |
dc.identifier.doi | 10.1371/journal.pone.0148537 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1932-6203 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1371/journal.pone.0148537 | es_ES |
dc.identifier.journal | PloS one | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |